Accelerating drug repurposing for rare neurological, neurometabolic and neuromuscular diseases by exploiting SIMilarities in clinical and molecular PATHology
---- Website under construction ----
SIMPATHIC is an EU-project. The SIMPATHIC Consortium comprises of 22 international partners, spread across Europe and Canada, including several university medical centers and patient organizations. SIMPATHIC focuses on expediting the drug repurposing process and enhancing every aspect of it.
What is SIMPATHIC?
SIMPATHIC aims to unveil the untapped potential of repurposing strategies for rare disorders by bringing together patients, researchers and legislators, and using innovative techniques and advanced clinical trials, to get appropriate drugs in time for those to whom little or no treatment is available today.
Who is SIMPATHIC?
Want to participate or receive more information?
The EU-project SIMPATHIC has been awarded 8-8 million euros for accelerated drug repurposing for rare neurological disorders.
29 February 2024 – Rare Disease Day